MAIA Biotechnology, Inc.
MAIAMAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Q3 2027
Market Overview
Stock performance and key metrics
2 upcoming, 1 past
How MAIA's past catalysts played out
Cemiplimab
Carcinoma, Non-Small -Cell Lung
6-Thio-2'-Deoxyguanosine
Carcinoma, Non-Small-Cell Lung
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cemiplimab | Phase 3 | Carcinoma, Non-Small -Cell Lung | - | - |
6-Thio-2'-Deoxyguanosine | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MAIA Biotechnology, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in MAIA Biotechnology, Inc.'s (MAIA) pipeline across Phase 3. Its lead program is Cemiplimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MAIA Biotechnology, Inc.'s next FDA catalyst?→
MAIA Biotechnology, Inc.'s (MAIA) next tracked catalyst is a Earnings expected August 10, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MAIA biotech catalysts?→
Add MAIA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MAIA Biotechnology, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.